ENTRY       D10827            Mixture   Drug
NAME        Sofosbuvir and velpatasvir;
            Epclusa (TN)
PRODUCT     EPCLUSA (Gilead Sciences)
  GENERIC   SOFOSBUVIR AND VELPATASVIR (Asegua Therapeutics LLC)
COMPONENT   Sofosbuvir [DR:D10366], Velpatasvir [DR:D10806]
CLASS       Antiviral
             DG03198  Anti-HCV agent
            Metabolizing enzyme substrate
             DG02919  CYP2B6 substrate
             DG02918  CYP2C8 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
            Transporter inhibitor
             DG01622  ABCB1 inhibitor
             DG02862  ABCG2 inhibitor
             DG02865  SLCO1B1 inhibitor
             DG02907  SLCO1B3 inhibitor
REMARK      Therapeutic category: 6250
            ATC code: J05AP55
            Product: D10827<JP/US>
EFFICACY    Antiviral
  DISEASE   Hepatitis C virus infection [DS:H00413]
COMMENT     Sofosbuvir and Velpatasvir are substrates of BCRP and P-gp.
            Velpatasvir is metabolized by CYP2B6, CYP2C8 and CYP3A4, and it is an inhibitor of the following transporters: P-gp, BCRP, OATP1B1 and OATP1B3.
TARGET      HCV NS5A [KO:K22275]
            HCV NS5B [KO:K22472]
METABOLISM  Enzyme: CYP2B6 [HSA:1555], CYP2C8 [HSA:1558], CYP3A4 [HSA:1576]
            Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
INTERACTION Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AP Antivirals for treatment of HCV infections
                 J05AP55 Sofosbuvir and velpatasvir
                  D10827  Sofosbuvir and velpatasvir &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-hepatitis C (HCV) Agents
               Sofosbuvir/ Velpatasvir
                D10827  Sofosbuvir and velpatasvir
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D10827  Sofosbuvir and velpatasvir
            Drug groups [BR:br08330]
             Antiviral
              DG03198  Anti-HCV agent
               D10827  Sofosbuvir and velpatasvir
             Metabolizing enzyme substrate
              DG02919  CYP2B6 substrate
               D10827  Sofosbuvir and velpatasvir
              DG02918  CYP2C8 substrate
               D10827  Sofosbuvir and velpatasvir
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D10827  Sofosbuvir and velpatasvir
             Transporter substrate
              DG01665  ABCB1 substrate
               D10827  Sofosbuvir and velpatasvir
              DG01913  ABCG2 substrate
               D10827  Sofosbuvir and velpatasvir
             Transporter inhibitor
              DG01622  ABCB1 inhibitor
               D10827  Sofosbuvir and velpatasvir
              DG02862  ABCG2 inhibitor
               D10827  Sofosbuvir and velpatasvir
              DG02865  SLCO1B1 inhibitor
               D10827  Sofosbuvir and velpatasvir
              DG02907  SLCO1B3 inhibitor
               D10827  Sofosbuvir and velpatasvir
            Drug classes [BR:br08332]
             Antiviral
              DG03198  Anti-HCV agent
               D10827  Sofosbuvir and velpatasvir
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HCV NS5A/NS5B inhibitor
                D10827  Sofosbuvir and velpatasvir &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10827
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10827
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10827
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10827
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10827
             Drug transporters
              D10827
DBLINKS     PubChem: 319902627
///
